Curanex Pharmaceuticals(CURX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CURX Curanex Pharmaceuticals

Market Closed 01-09 16:00:00 EST

0.3750

+0.0047

+1.27%

盘后0.4000

+0.0250+6.67%

19:57 EST

High0.3800	Low0.3505	Vol69.10K
Open0.3505	D1 Closing0.3703	Amplitude7.97%
Mkt Cap10.63M	Tradable Cap3.41M	Total Shares28.34M
T/O25.54K	T/O Rate0.76%	Tradable Shares9.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CURX","market":"US","secType":"STK","nameCN":"Curanex Pharmaceuticals","latestPrice":0.375,"timestamp":1767992400000,"preClose":0.3703,"halted":0,"volume":69099,"hourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.375,"latestTime":"19:57 EST","volume":509,"amount":199.0263,"timestamp":1768006672296},"delay":0,"floatShares":9093100,"shares":28340800,"eps":-0.04552,"marketStatus":"Market Closed","change":0.0047,"latestTime":"01-09 16:00:00 EST","open":0.3505,"high":0.38,"low":0.3505,"amount":25537.705159,"amplitude":0.079665,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.04552,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"listingDate":1756180800000,"exchange":"NASDAQ","adjPreClose":0.3703,"preHourTrading":{"tag":"盘前","latestPrice":0.3761,"preClose":0.3703,"latestTime":"09:28 EST","volume":1053,"amount":395.722402,"timestamp":1767968894410},"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.375,"latestTime":"19:57 EST","volume":509,"amount":199.0263,"timestamp":1768006672296},"volumeRatio":0.7199552391077891},"requestUrl":"/m/hq/s/CURX/wiki","defaultTab":"wiki","newsList":[{"id":"2601583294","title":"Curanex Pharmaceuticals Inc - Haiyan Yang Resigns as CFO and Treasurer of Curanex - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601583294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601583294?lang=en_us&edition=fundamental","pubTime":"2026-01-06 04:45","pubTimestamp":1767645917,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CURX","BK4007"],"gpt_icon":0},{"id":"2601329928","title":"Curanex Pharmaceuticals Sets CFO Compensation at $20,000 Per Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2601329928","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601329928?lang=en_us&edition=fundamental","pubTime":"2026-01-06 04:43","pubTimestamp":1767645839,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. has appointed Wanjun Zhang as its new Chief Financial Officer and Treasurer, effective January 1, 2026, following the resignation of Haiyan Yang. In connection with his appointment, the company entered into a consulting agreement with Mr. Zhang for an initial term of two years. Under the agreement, Mr. Zhang will receive an annual compensation of $20,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL8QQQxp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CURX"],"gpt_icon":0},{"id":"2584647671","title":"Curanex Pharmaceuticals Delays Quarterly Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2584647671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584647671?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:30","pubTimestamp":1763379027,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. has disclosed a delay in filing its quarterly report on Form 10-Q for the financial period ended September 30, 2025. The company cited that the report could not be filed on time without unreasonable effort or expense and expects to submit the filing within the allowed extension period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4NxqSb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"gpt_icon":0},{"id":"2581190100","title":"Curanex Pharmaceuticals Faces Nasdaq Delisting Warning","url":"https://stock-news.laohu8.com/highlight/detail?id=2581190100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581190100?lang=en_us&edition=fundamental","pubTime":"2025-11-07 02:57","pubTimestamp":1762455452,"startTime":"0","endTime":"0","summary":"The latest update is out from Curanex Pharmaceuticals Inc. ( ($CURX) ). On November 5, 2025, Curanex Pharmaceuticals Inc. received a notification f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curanex-pharmaceuticals-faces-nasdaq-delisting-warning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curanex-pharmaceuticals-faces-nasdaq-delisting-warning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["USAW.SI","NVIW.SI","TSYW.SI",".IXIC","BK4007","QLD","CURX","SQQQ","TQQQ","MNQmain","PSQ","USJW.SI","NQmain","QID"],"gpt_icon":0},{"id":"2581019155","title":"Curanex Pharmaceuticals Receives Nasdaq Delisting Warning for Low Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2581019155","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581019155?lang=en_us&edition=fundamental","pubTime":"2025-11-07 02:41","pubTimestamp":1762454465,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. announced that it has received a notice from the Nasdaq Stock Market indicating that its common stock has closed below the required minimum bid price of $1.00 per share for 30 consecutive business days. This triggers a potential delisting issue under Nasdaq Listing Rule 5550. The company has 180 calendar days, until May 4, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. During this period, Curanex's stock will continue to trade on the Nasdaq Capital Market under the symbol \"CURX\". If compliance is not regained, the company may be eligible for an additional 180-day extension or could face delisting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbzL8P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CURX"],"gpt_icon":0},{"id":"2577365399","title":"Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2577365399","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577365399?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:00","pubTimestamp":1761130800,"startTime":"0","endTime":"0","summary":"Jericho, New York, Oct.  22, 2025  (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3170944/0/en/Curanex-Pharmaceuticals-Inc-Engages-Strategic-Investor-Relations-to-Enhance-Investor-Communications-and-Engagement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"gpt_icon":0},{"id":"2571350233","title":"Curanex Pharmaceuticals Issues Shares Post-IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350233?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:18","pubTimestamp":1759177085,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. ( ($CURX) ) has issued an update. On September 25, 2025, Curanex Pharmaceuticals Inc. issued 28,312 shares of common s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curanex-pharmaceuticals-issues-shares-post-ipo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curanex-pharmaceuticals-issues-shares-post-ipo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CURX","POST","BK4212"],"gpt_icon":0},{"id":"2571478357","title":"Curanex Pharmaceuticals Issues 28,312 Shares in Private Placement and 4.3 Million Shares Through IPO and Over-Allotment","url":"https://stock-news.laohu8.com/highlight/detail?id=2571478357","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571478357?lang=en_us&edition=fundamental","pubTime":"2025-09-30 03:56","pubTimestamp":1759175772,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. issued 28,312 shares of common stock to investor Xiaohong Song for $200,000, following the company's initial public offering . Additionally, Curanex completed its IPO on August 27, 2025, issuing 3,750,000 shares to underwriters, and on September 12, 2025, issued another 562,500 shares upon full exercise of the over-allotment option.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL87lsc9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"gpt_icon":0},{"id":"2568902644","title":"Curanex Pharmaceuticals Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2568902644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568902644?lang=en_us&edition=fundamental","pubTime":"2025-09-17 23:20","pubTimestamp":1758122418,"startTime":"0","endTime":"0","summary":"11:18 EDT Curanex (CURX) Pharmaceuticals Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curanex-pharmaceuticals-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curanex-pharmaceuticals-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CURX","BK4007"],"gpt_icon":0},{"id":"2567909675","title":"Curanex Pharmaceuticals Boosts IPO Proceeds with Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2567909675","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567909675?lang=en_us&edition=fundamental","pubTime":"2025-09-13 03:17","pubTimestamp":1757704656,"startTime":"0","endTime":"0","summary":"An announcement from Curanex Pharmaceuticals Inc. ( ($CURX) ) is now available. On August 27, 2025, Curanex Pharmaceuticals Inc closed its initial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curanex-pharmaceuticals-boosts-ipo-proceeds-with-share-sale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curanex-pharmaceuticals-boosts-ipo-proceeds-with-share-sale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CURX"],"gpt_icon":0},{"id":"2567783906","title":"Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters","url":"https://stock-news.laohu8.com/highlight/detail?id=2567783906","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567783906?lang=en_us&edition=fundamental","pubTime":"2025-09-13 02:46","pubTimestamp":1757702760,"startTime":"0","endTime":"0","summary":"Jericho, New York, Sept.  12, 2025  (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/12/3149402/0/en/Curanex-Pharmaceuticals-Inc-Announces-Exercise-of-the-Over-Allotment-Option-by-Underwriters.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"gpt_icon":0},{"id":"2566161062","title":"Curanex Pharmaceuticals Reports No Revenue for Q2 2025, General and Administrative Expenses Rise 30% from Q2 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2566161062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566161062?lang=en_us&edition=fundamental","pubTime":"2025-09-10 03:29","pubTimestamp":1757446183,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. recently reported its quarterly results for the period ending June 30, 2025. The company did not generate any revenue during the three months ended June 30, 2025, which aligns with its ongoing focus on the development of botanical drug candidates and achieving clinical and regulatory milestones. Operating expenses saw an increase, with general and administrative expenses rising to $57,658 for the three months ended June 30, 2025, compared to $44,200 for the same period in 2024. This increase is attributed mainly to the ongoing costs related to the company's preparation for an initial public offering  and maintaining readiness for operating as a public company. For the six-month period ending June 30, 2025, Curanex also reported no revenue, consistent with its strategic focus. General and administrative expenses for this period increased to $195,110 from $124,401 in the same period in 2024, again primarily due to IPO-related costs. The company has stated tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL5MC2R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX"],"gpt_icon":0},{"id":"2564332635","title":"Curanex Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for COO Liqin Xie","url":"https://stock-news.laohu8.com/highlight/detail?id=2564332635","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564332635?lang=en_us&edition=fundamental","pubTime":"2025-09-03 08:31","pubTimestamp":1756859482,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals Inc. has filed an initial statement of beneficial ownership. The filing identifies Xie Liqin as the beneficial owner, who serves as the Chief Operating Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDLbvgNW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CURX"],"gpt_icon":0},{"id":"2562778474","title":"Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2562778474","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562778474?lang=en_us&edition=fundamental","pubTime":"2025-08-28 05:00","pubTimestamp":1756328400,"startTime":"0","endTime":"0","summary":"Jericho, New York, Aug.  27, 2025  (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (\"Curanex\" or the \"Company\"), a developmental stage pharmaceutical company focused on discovering and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3140432/0/en/Curanex-Pharmaceuticals-Inc-Announces-Closing-of-its-Initial-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX"],"gpt_icon":0},{"id":"1176815931","title":"Stock Track | Curanex Pharmaceuticals Plummets 9.75% Following IPO Pricing at $4.00 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1176815931","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176815931?lang=en_us&edition=fundamental","pubTime":"2025-08-26 22:46","pubTimestamp":1756219584,"startTime":"0","endTime":"0","summary":"Shares of Curanex Pharmaceuticals (NASDAQ: CURX) plummeted 9.75% in Tuesday's intraday trading session, following the announcement of its initial public offering (IPO) pricing. The developmental...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CURX"],"gpt_icon":0},{"id":"2562373372","title":"Curanex Pharmaceuticals Prices $15 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2562373372","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562373372?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:55","pubTimestamp":1756209321,"startTime":"0","endTime":"0","summary":"Curanex Pharmaceuticals  said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CURX"],"gpt_icon":0},{"id":"2562738055","title":"BRIEF-Curanex Pharmaceuticals Announces Pricing Of Its Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2562738055","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562738055?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:31","pubTimestamp":1756207879,"startTime":"0","endTime":"0","summary":"BRIEF-Curanex Pharmaceuticals Announces Pricing Of Its Initial Public OfferingAug 26 (Reuters) - Curanex Pharmaceuticals Inc CURX.O:CURANEX PHARMACEUTICALS INC. ANNOUNCES PRICING OF ITS INITIAL PUBLIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nTUA2WCK9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX"],"gpt_icon":0},{"id":"2562738765","title":"Curanex Pharmaceuticals Inc - Proceeds to Develop Phyto-N for Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2562738765","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562738765?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:30","pubTimestamp":1756207800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nTUA2WCK9C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CURX"],"gpt_icon":0},{"id":"2562387957","title":"Curanex Pharmaceuticals Inc - Offering of 3,750,000 Shares at $4.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2562387957","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562387957?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:30","pubTimestamp":1756207800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nTUA2WCK9C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CURX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.curanexpharma.com","stockEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":-0.1873},{"period":"3month","weight":-0.4631},{"period":"6month","weight":-0.9063},{"period":"ytd","weight":0.1343}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Curanex Pharmaceuticals","nameEN":"Curanex Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Curanex Pharmaceuticals(CURX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Curanex Pharmaceuticals(CURX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Curanex Pharmaceuticals,CURX,Curanex Pharmaceuticals股票,Curanex Pharmaceuticals股票老虎,Curanex Pharmaceuticals股票老虎国际,Curanex Pharmaceuticals行情,Curanex Pharmaceuticals股票行情,Curanex Pharmaceuticals股价,Curanex Pharmaceuticals股市,Curanex Pharmaceuticals股票价格,Curanex Pharmaceuticals股票交易,Curanex Pharmaceuticals股票购买,Curanex Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Curanex Pharmaceuticals(CURX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Curanex Pharmaceuticals(CURX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}